24.05.2024 – 13:02
ERA Congress
Stockholm (ots/PRNewswire)
The fundamental analysis, right now in its 61st yr,St Presented on the ERA Congress, semaglutide confirmed that semaglutide considerably reduces the danger of extreme kidney illness, cardiovascular outcomes and all-cause mortality in sufferers with sort 2 diabetes and continual kidney illness.
In the FLOW examine (Check Renal Fanointing with Semaglit is not too late Oextra Weekly) is a double-blind, randomized, placebo-controlled worldwide examine with 3,533 sufferers and a follow-up interval of three.4 years. The examine was designed to guage the efficacy and security of semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, within the prevention of acute kidney harm, particularly renal failure, extreme lack of renal operate, and demise from kidney illness or coronary heart illness, in people these with sort 2 diabetes and continual kidney illness. Patients obtained semaglutide 1.0 mg as soon as weekly or placebo.
Participants who obtained semaglutide had a 24% decrease danger of the first composite endpoint, together with kidney harm and demise from cardiovascular and renal causes, in comparison with contributors who obtained placebo. This discount in danger was constant for each kidney-specific and cardiovascular mortality.
Semaglutide additionally reveals a major enchancment within the second finish. The general improve in eGFR was slower by 1.16 ml/min/1.73m2/yr, the danger of main cardiovascular occasions was lowered by 18% and the danger of all-cause mortality was lowered by 20%.
Professor Vlado Perkovic commented: “The use of semaglutide in individuals with sort 2 diabetes and continual kidney illness can scale back the danger of extreme kidney harm and the danger of cardiovascular occasions, cardiac demise and general demise. These advantages symbolize a profound scientific impact on the kidneys “Furthermore, the convincing security outcomes assist the very best quantity of semaglutide on this space.”
Chronic kidney illness impacts greater than 800 million individuals worldwide and is extra frequent in individuals with sort 2 diabetes. Chronic kidney illness carries a major danger of kidney failure, cardiovascular occasions, and demise, highlighting the pressing want for analysis into its prevention and therapy.
The FLOW examine was overseen by a study-led steering committee in collaboration with examine sponsor Novo Nordisk, which additionally led examine actions. The examine was revealed right now within the New England Journal of Medicine and was offered on the 61st ERA Congress in Stockholm, Sweden.
View authentic content material: https://www.prnewswire.com/news-releases/61-era-kongress-semaglutid-reduziert-signifikant-das-risiko-fur-schwerwiegende-nierenerkrankungen-kardiovasculare-folgen-und-sterblichkeit-bei-patienten-mit- typ-2-diabetes-und-chronischer-nierenerkrankung-bahnbrechende-studie-302152931.html
Press the contact:
Luke Paskins,
[email protected]; +44 (0)7837 684372
Original content material from: ERA Congress, broadcast by information aktuell